Stakeholder Opinions: Traumatic Brain Injury Hormonal therapy generates optimism
There remains no approved pharmacological or cellular treatment to improve the outcome of survivors of traumatic brain injury (TBI). In the past two decades, understanding of the cellular and molecular mechanisms that occur after TBI has grown and a combination of novel therapeutic strategies and approved molecules are presently being examined in clinical trials.
Scope
*Analysis of the patient potential of traumatic brain injury across the seven major markets and several rest of world markets.
*Review of key unmet clinical needs in the treatment of traumatic brain injury and current pipeline treatments.
*Identification of key opportunities and threats facing developers of treatments for traumatic brain injury.
*Insight from six internationally recognized key opinion leaders in the field of spinal cord injuries.
Highlights
The incidence of hospitalized cases of TBI is estimated to be higher than the annual incidence of several medical conditions including some cancer types, epilepsy, HIV/AIDS, multiple sclerosis and spinal cord injury. Therefore, developers of efficacious treatments for TBI stand to benefit from a sizeable patient population.
Despite the high level of unmet need in the treatment of TBI, TBI research is under-funded. The current situation may stem from poor awareness of TBI, pessimism resulting from the relatively high attrition rate in the TBI pipeline and the perception that an efficacious pharmacological treatment for TBI is unattainable.
A sizeable proportion of the clinical candidates are under development as neuroprotective treatments for TBI. The inclusion of two progesterone receptor agonists in the current pipeline is indicative of the rising level of optimism regarding the neuroprotective potential of progesterone in TBI.
Reasons to Purchase
*Quantify the incidence of hospitalized cases of TBI across the seven major pharmaceutical markets and identify key clinical unmet needs.
*Assess the opportunities and threats facing developers in the traumatic brain injury market.
*Utilize pipeline product profiles to identify potential in-licensing opportunities.
Buy Now : Market Research
Related Reports
- Traumatic Brain Injury
- Stakeholder Opinions: Spinal Cord Injury – Attractive niche market with multi-billion dollar potential
- Stakeholder Opinions: Gene Therapy – Gene therapy to deliver after 20 years of clinical development
- Stakeholder Opinions: Ovarian Cancer – Approaching the era of molecular targeted therapy
- Stakeholder Opinions: Gastric Cancer – Targeted therapies compete for first-to-market status
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) – Opportunities in China, India, South Korea and Taiwan
- Stakeholder Opinions: Melanoma Future treatment will be based on individual tumor gene expression signatures
- Stakeholder Opinions: Vaccine antigen delivery technologies – Molecular systems to open new markets
- Stakeholder Opinions: Ophthalmology – Leading brands under threat
